Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
Flaherty KR et al.
Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?
Chaudhuri N et al.
Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial
Valenzuela C et al.
Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?
Richeldi L et al.
Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)
Bonella F et al.
King’s Brief Interstitial Lung Disease (K-BILD) questionnaire: content relevance in progressive fibrosing ILD (PF-ILD)
Birring SS et al.
Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry
Griese M et al.
